AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
peramivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals neuraminidase inhibitors | 4823 | 330600-85-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Peramivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| fu (Fraction unbound in plasma) | 1 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| CL (Clearance) | 1.46 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| BA (Bioavailability) | 0 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 13, 2018 | EMA | BIOCRYST UK LIMITED | |
| Dec. 19, 2014 | FDA | BIOCRYST |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AH03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Neuraminidase inhibitors |
| FDA MoA | N0000175436 | Neuraminidase Inhibitors |
| FDA EPC | N0000175524 | Neuraminidase Inhibitor |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:36044 | antiviral drug |
| CHEBI has role | CHEBI:52425 | EC 3.2.1.18 (<i>exo</i>-α-sialidase) inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
Related Drugs by ATC class:
J05AH Neuraminidase inhibitors 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Influenza | indication | 6142004 | DOID:8469 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.6 | acidic |
| pKa2 | 12.05 | acidic |
| pKa3 | 13.73 | acidic |
| pKa4 | 10.07 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 10391075 | Feb. 12, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER |
| 200MG/20ML (10MG/ML) | RAPIVAB | BIOCRYST | N206426 | Dec. 19, 2014 | RX | SOLUTION | INTRAVENOUS | 8778997 | May 7, 2027 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sialidase 2 | Enzyme | Ki | 4.25 | CHEMBL | |||||
| Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.85 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | INHIBITOR | IC50 | 8.30 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | INHIBITOR | Ki | 9.08 | CHEMBL | DRUG LABEL | |||
| Neuraminidase | Enzyme | IC50 | 9.40 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 10.15 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 8.70 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 7.03 | CHEMBL | |||||
| Sialidase | Enzyme | IC50 | 4.40 | CHEMBL | |||||
| Neuraminidase | Enzyme | IC50 | 9.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03829 | KEGG_DRUG |
| 1041434-82-5 | SECONDARY_CAS_RN |
| 4034033 | VANDF |
| CHEBI:85196 | CHEBI |
| BCZ | PDB_CHEM_ID |
| CHEMBL3989402 | ChEMBL_ID |
| CHEMBL139367 | ChEMBL_ID |
| C414210 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB06614 | DRUGBANK_ID |
| 1598078 | RXNORM |
| 231961 | MMSL |
| 30814 | MMSL |
| d08335 | MMSL |
| 013296 | NDDF |
| 716121006 | SNOMEDCT_US |
| 763542005 | SNOMEDCT_US |
| C1675326 | UMLSCUI |
| 154234 | PUBCHEM_CID |
| QW7Y7ZR15U | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61364-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 27 sections |
| Rapivab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72769-181 | SOLUTION | 600 mg | INTRAVENOUS | NDA | 30 sections |